Regional radiochemotherapy using in situ hydrogel

被引:29
作者
Azhdarinia, A [1 ]
Yang, DJ [1 ]
Yu, DF [1 ]
Mendez, R [1 ]
Oh, C [1 ]
Kohanim, S [1 ]
Bryant, J [1 ]
Kim, EE [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Div Diagnost Imaging, Houston, TX 77030 USA
关键词
chemotherapy; hydrogel; radiotherapy; Rhenium-188;
D O I
10.1007/s11095-005-2594-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the feasibility of regional radiochemotherapy of mammary tumors using in situ hydrogel loaded with cisplatin ( CDDP) and rhenium-188 (Re-188). Methods. Sodium alginate ( SA) and calcium chloride were used to create a hydrogel for delivery of CDDP and 188Re. In vitro studies were performed to evaluate cytotoxic effects of Re-188-hydrogel and sustained-release ability of the CDDP-hydrogel. Tumor-bearing rats were injected with Re-188-hydrogel (0.5 - 1 mCi/rat), Re-188-perrhenate ( 0.5 - 1 mCi/rat, intratumoral, I. T.), CDDP-hydrogel ( 3 mg/kg), and Re-188-hydrogel loaded with CDDP ( 3 mg/kg body weight, 0.5 - 1 mCi/rat), respectively, and groups receiving Re-188 were imaged at 24 and 48 h postinjection. Tumor volume, body weight, imaging, and kidney function were assessed as required for each group. Results. Successful formation of the hydrogel was demonstrated by cytotoxic effects of Re-188-hydrogel and slow release of CDDP-hydrogel in vitro. Tumor volume measurements showed significant delay in tumor growth in treated vs. control groups with minimal variation in normal kidney function for the CDDP-hydrogel group. Scintigraphic images indicated localization of Re-188-hydrogel in the tumor site up to 48 h postinjection. Conclusions. Our data demonstrate the feasibility of using hydrogel for delivery of chemotherapeutics and radiation locally. This technique may have applications involving other contrast modalities as well as treatment in cases where tumors are inoperable.
引用
收藏
页码:776 / 783
页数:8
相关论文
共 40 条
[31]   Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation [J].
Reske, SN ;
Bunjes, D ;
Buchmann, I ;
Seitz, U ;
Glatting, G ;
Neumaier, B ;
Kotzerke, J ;
Buck, A ;
Martin, H ;
Döhner, H ;
Bergmann, L .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) :807-815
[32]  
Schaffland AO, 2004, J NUCL MED, V45, P1784
[33]  
Scheffler Justyna, 2003, Nucl Med Rev Cent East Eur, V6, P55
[34]  
Srivastava SC, 1998, CLIN CANCER RES, V4, P61
[35]   Alginate in drug delivery systems [J].
Tonnesen, HH ;
Karlsen, J .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (06) :621-630
[36]   Radiation dosimetry results front a phase II trial of ibritumomab tiuxetan (Zevalin™) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia [J].
Wiseman, GA ;
Leigh, BR ;
Erwin, WD ;
Sparks, RB ;
Podoloff, DA ;
Schilder, RJ ;
Bartlett, NL ;
Spies, SM ;
Grillo-López, AJ ;
Witzig, TE ;
White, CA .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) :165-178
[37]   Endovascular irradiation with the liquid β-emitter Rhenium-188 to reduce restenosis after experimental wall injury [J].
Wohlfrom, M ;
Kotzerke, J ;
Kamenz, J ;
Eble, M ;
Hess, B ;
Wöhrle, J ;
Reske, SN ;
Hombach, V ;
Hanke, H ;
Höher, M .
CARDIOVASCULAR RESEARCH, 2001, 49 (01) :169-176
[38]   Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system:: Feasibility study with rodents [J].
Yang, DJ ;
Kim, CG ;
Schechter, NR ;
Azhdarinia, A ;
Yu, DF ;
Oh, CS ;
Bryant, JL ;
Won, JJ ;
Kim, EE ;
Podoloff, DA .
RADIOLOGY, 2003, 226 (02) :465-473
[39]   Pretargeted α emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N,N′,N",N′"-tetraacetic acid-biotin [J].
Yao, ZS ;
Zhang, ML ;
Garmestani, K ;
Axworthy, DB ;
Mallett, RW ;
Fritzberg, AR ;
Theodore, LJ ;
Plascjak, PS ;
Eckelman, WC ;
Waldmann, TA ;
Pastan, I ;
Paik, CH ;
Brechbiel, MW ;
Carrasquillo, JA .
CLINICAL CANCER RESEARCH, 2004, 10 (09) :3137-3146
[40]   Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients [J].
Zhang, H ;
Tian, M ;
Li, SJ ;
Liu, JZ ;
Tanada, S ;
Endo, K .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (05) :719-726